Open-Label Extension of LOCKCYST Trial

Inclusion Criteria: * Participated in the LOCKCYST trial * 18 yrs-of age * Multiple cysts \> 20 * Cooperating patient * Is willing and able to comply with the study drug regimen and all other study requirements. * Willingness to give written informed consent Exclusion Criteria: * Use of oral anticonceptives or estrogen suppletion * Females who are pregnant or breast-feeding * History or other evidence of chronic pulmonary disease associated with functional limitation * History of severe cardiac disease (eg, NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases). In addition, patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled. * History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study * Symptomatic gallstones (lanreotide decreases gall bladder volume) * Renal failure requiring hemodialysis